CD274 and melanoma: Nexturastat A was investigated more thoroughly in the BRAFV600E SM1 melanoma model, where it leveled the increased PD-L1 expression upon anti-PD-1 therapy, promoted tumor infiltration by immune cells, and suppressed pro-tumorigenic M2-polarized macrophages.